United States //   News Releases

News Releases

News Releases

Date Title and Summary Additional Formats
Toggle Summary Endologix Presents Positive Two-Year Clinical Data from the Nellix® EVAS FORWARD IDE Trial
IRVINE, Calif. --(BUSINESS WIRE)-- Endologix, Inc. (Nasdaq:ELGX), a developer and marketer of innovative treatments for aortic disorders, today announced the presentation of two-year clinical data from the Company's Nellix® EVAS FORWARD IDE trial that prospectively enrolled patients with abdominal
View HTML
Toggle Summary Endologix Reports Positive Clinical Data from the Ovation LUCY Study
First Prospective Clinical Trial to Evaluate Endovascular Aneurysm Repair (EVAR) in Women IRVINE, Calif. --(BUSINESS WIRE)-- Endologix, Inc. (Nasdaq:ELGX), a developer and marketer of innovative treatments for aortic disorders, today announced 30-day results from the LUCY (Evaluation of Fema L es
View HTML
Toggle Summary Endologix Provides an Update on the Nellix® Endovascular Aneurysm Sealing System U.S. Regulatory Status
Company to Host an Investor Conference Call on May 18, 2017 at 7:30 a.m. ET IRVINE, Calif. --(BUSINESS WIRE)-- Endologix, Inc. (Nasdaq:ELGX), a developer and marketer of innovative treatments for aortic disorders, today announced that the Company met with the Food and Drug Administration (FDA)
View HTML
Toggle Summary Endologix Reports First Quarter 2017 Financial Results
IRVINE, Calif. --(BUSINESS WIRE)-- Endologix, Inc. (NASDAQ:ELGX), a developer and marketer of innovative treatments for aortic disorders, today announced financial results for the three months ended March 31, 2017 . "We are pleased with our progress during the quarter and our solid start to the
View HTML
Toggle Summary Endologix, Inc. to Host an Investor Conference Call to Discuss its Nellix® Endovascular Aneurysm Sealing System Presentation at the Society of Vascular Surgery Annual Meeting on June 3, 2017
IRVINE, Calif. --(BUSINESS WIRE)-- Endologix , Inc. (Nasdaq: ELGX), a developer and marketer of innovative treatments for aortic disorders, today announced that Dr. Jeffrey Carpenter's submission "Refinement of the IFU for the Nellix® System for Endovascular Aneurysm Sealing Based Upon Outcomes
View HTML
Toggle Summary Endologix, Inc. to Announce First Quarter 2017 Financial Results on May 4, 2017
IRVINE, Calif. --(BUSINESS WIRE)-- Endologix , Inc. (Nasdaq:ELGX), a developer and marketer of innovative treatments for aortic disorders, today announced that it will report financial results for the first quarter of fiscal year 2017 after the market close on Thursday, May 4, 2017 .
View HTML
Toggle Summary Endologix Enters into $170 Million Credit Facility with Deerfield Management
IRVINE, Calif. --(BUSINESS WIRE)-- Endologix, Inc. (Nasdaq:ELGX), a developer and marketer of innovative treatments for aortic disorders, today announced that it has entered into an agreement with Deerfield Management ("Deerfield"), a leading healthcare investment organization, to provide Endologix
View HTML
Toggle Summary Endologix, Inc. Announces Enrollment of First Patients in ELEVATE IDE Clinical Study
IRVINE, Calif. --(BUSINESS WIRE)-- Endologix, Inc. (Nasdaq:ELGX), a developer and marketer of innovative treatments for aortic disorders, announced today that the first patients were treated in the E xpanding Patient Applicability with Po l ymer S e aling O vat ion Alto St e nt Graft (ELEVATE) IDE
View HTML
Toggle Summary Endologix, Inc. to Present at the Oppenheimer 27th Annual Healthcare Conference
IRVINE, Calif. --(BUSINESS WIRE)-- Endologix , Inc. (Nasdaq:ELGX), a developer and marketer of innovative treatments for aortic disorders, today announced that John McDermott , Chairman and Chief Executive Officer, will present at the Oppenheimer 27 th Annual Healthcare Conference at 8:35 a.m.
View HTML
Toggle Summary Endologix Reports Results for the Fourth Quarter and Full Year 2016
IRVINE, Calif. , Feb. 22, 2017 (GLOBE NEWSWIRE) -- Endologix, Inc. (NASDAQ:ELGX), developer and marketer of innovative treatments for aortic disorders, today announced financial results for the three and twelve months ended December 31, 2016 . John McDermott , Endologix Chief Executive Officer,
View HTML
Toggle Summary Endologix Completes Patient Enrollment in the Ovation® LUCY Study
First Prospective Study Evaluating EVAR in a Female Population
View HTML
Toggle Summary Endologix to Report Fourth Quarter and Full Year 2016 Financial Results on February 22, 2017
IRVINE, Calif. , Feb. 07, 2017 (GLOBE NEWSWIRE) -- Endologix, Inc. (NASDAQ:ELGX), developer and marketer of innovative treatments for aortic disorders, announced today details relating to the release of its fourth quarter and full year 2016 financial results, which will take place on Wednesday,
View HTML
Toggle Summary Endologix Announces Appointment of Dan Lemaitre as Chairman of the Board
John McDermott to Continue as Chief Executive Officer IRVINE, Calif. , Feb. 06, 2017 (GLOBE NEWSWIRE) -- Endologix, Inc. (Nasdaq:ELGX), developer and marketer of innovative treatments for aortic disorders, today announced that its Board of Directors has elected to separate the positions of Chairman
View HTML
Toggle Summary Endologix to Present at Leerink Partners 6th Annual Global Healthcare Conference
IRVINE, Calif. , Feb. 03, 2017 (GLOBE NEWSWIRE) -- Endologix, Inc. (Nasdaq:ELGX), developer and marketer of innovative treatments for aortic disorders, announced today that Vaseem Mahboob , Chief Financial Officer, is scheduled to present at Leerink Partners 6 th Annual Global Healthcare Conference
View HTML
Toggle Summary Endologix Announces Reinstatement of CE Mark for AFX® and AFX2 Endovascular AAA Systems
IRVINE, Calif. , Jan. 25, 2017 (GLOBE NEWSWIRE) -- Endologix, Inc. (Nasdaq:ELGX), developer and marketer of innovative treatments for aortic disorders, today announced that it received notice from its Notified Body in the European Union that the CE Mark for the AFX® and AFX2 Endovascular AAA
View HTML